<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097448</url>
  </required_header>
  <id_info>
    <org_study_id>DC006296</org_study_id>
    <secondary_id>U01DC006296</secondary_id>
    <secondary_id>03-11-055</secondary_id>
    <nct_id>NCT00097448</nct_id>
  </id_info>
  <brief_title>Sudden Deafness Treatment Trial</brief_title>
  <acronym>SSNHL</acronym>
  <official_title>Sudden Hearing Loss Multicenter Treatment Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected
      into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing
      loss (inner ear hearing loss affecting one ear that occurs over less than 72 hours).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sudden deafness is believed to affect 1:5000 people yearly. The cause is unknown. Spontaneous
      improvement is seen in approximately 20% of subjects. Improvement is seen in approximately
      60% of subjects treated promptly with oral corticosteroids. Anecdotal case reports and
      uncontrolled case series have suggested the intratympanic corticosteroids may work as well or
      better than oral treatment. The risks of oral prednisone are well-known. In theory,
      intratympanic treatment should achieve a higher drug concentration at the target (inner ear)
      with less risk of systemic side effects. This study is a head-to-head comparison of oral
      prednisone vs. intratympanic methylprednisolone for primary treatment of idiopathic sudden
      deafness. The study is designed as a non-inferiority trial testing that hypothesis that
      intratympanic methylprednisolone is not inferior to oral prednisone treatment. Subjects
      assigned to the oral treatment arm receive 14 days of high dose prednisone (60mg/day)
      followed by a 5-day taper. Subjects assigned to the intratympanic treatment arm receive 4
      doses of methylprednisolone injected into the middle twice weekly for two weeks. The primary
      outcome measure is hearing as measured by pure tone audiometry. Secondary outcomes include
      word recognition hearing levels and safety issues of local vs. systemic steroid side-effects
      and pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hearing Improvement</measure>
    <time_frame>2 months</time_frame>
    <description>Change from baseline to 2mos of 4-frequency (500, 1000, 2000, 4000Hz) pure tone average.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Sudden Deafness</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nineteen days of oral prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Oral, 19 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone sodium succinate</intervention_name>
    <description>Four intratympanic injections delivered to the middle ear over 2 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men/women 18 years and older in good health

          -  Unilateral sensorineural hearing loss developing within 72 hours (SSNHL)

          -  Pure Tone Average (PTA) (500, 1000, 2000, 4000 Hz) &gt;/= 50 dB in the affected ear, with
             the affected ear &gt;/= 30 dB worse than contralateral ear in at least one of the four
             frequencies

          -  Symmetric hearing prior to onset of SSNHL

          -  Hearing loss must be idiopathic

          -  Hearing loss must have occurred within the past 14 days

          -  Must be able to read or write English or Spanish

        Exclusion Criteria:

        SYSTEMIC DISEASE

          -  &gt;21 days prior oral steroid treatment within preceding 30 days

          -  History of tuberculosis (TB) or positive PPD

          -  Insulin-dependent diabetes mellitus

          -  History of rheumatic disease, e.g., rheumatoid arthritis, scleroderma, lupus, etc.

          -  Serious psychiatric disease or psychiatric reaction to corticosteroids

          -  History of heart disease or transient ischemic attacks (TIAs)

          -  Prior treatment with chemotherapeutic or immunosuppressive drugs

          -  Pancreatitis

          -  Active peptic ulcer disease or history of gastrointestinal bleeding

          -  History of HIV, Hepatitis B or C

          -  Chronic kidney failure

          -  Alcohol abuse

          -  Active shingles

          -  Severe osteoporosis or non-surgical aseptic necrosis of the hip

        OTOLOGIC DISEASE

          -  Prior history of SSNHL

          -  History of fluctuating hearing loss

          -  History of Meniere's disease

          -  History of chronic ear infection

          -  History of otosclerosis

          -  History of ear surgery (except childhood pressure equalization [pe] tubes)

          -  History of congenital hearing loss

          -  History of trauma immediately preceding onset of SSNHL

          -  History of syphilitic hearing loss

          -  History of genetic/hereditary hearing loss

          -  Skull, facial, or temporal bone anomalies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Rauch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>House Ear Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8895</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida, College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye &amp; Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Ear Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.suddendeafness.org</url>
    <description>Sudden Deafness</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2004</study_first_submitted>
  <study_first_submitted_qc>November 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2004</study_first_posted>
  <results_first_submitted>November 8, 2012</results_first_submitted>
  <results_first_submitted_qc>February 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2013</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Steven Rauch, MD</investigator_full_name>
    <investigator_title>Professor of Otology and Laryngology, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>sudden hearing loss</keyword>
  <keyword>unilateral sudden sensorineural hearing loss</keyword>
  <keyword>sudden sensorineural hearing loss</keyword>
  <keyword>sudden unilateral hearing loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sudden</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive consenting adults with SSNHL from 16 academic medical centers around the United States.</recruitment_details>
      <pre_assignment_details>All subject presenting within 14 days of SSNHL onset.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Steroids</title>
          <description>Prednisone 60mg per day x 14 days, 5 day taper.</description>
        </group>
        <group group_id="P2">
          <title>Intratympanic Steroids</title>
          <description>1ml of methylprednisolone 10mg/ml. 4 doses over 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Steroids</title>
          <description>Prednisone 60mg per day x 14 days, 5 day taper.</description>
        </group>
        <group group_id="B2">
          <title>Intratympanic Steroids</title>
          <description>1ml of methylprednisolone 10mg/ml. 4 doses over 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="255"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="14"/>
                    <measurement group_id="B2" value="51" spread="15"/>
                    <measurement group_id="B3" value="50.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hearing Improvement</title>
        <description>Change from baseline to 2mos of 4-frequency (500, 1000, 2000, 4000Hz) pure tone average.</description>
        <time_frame>2 months</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Steroids</title>
            <description>Prednisone</description>
          </group>
          <group group_id="O2">
            <title>IT Steroids</title>
            <description>methylprednisolone</description>
          </group>
        </group_list>
        <measure>
          <title>Hearing Improvement</title>
          <description>Change from baseline to 2mos of 4-frequency (500, 1000, 2000, 4000Hz) pure tone average.</description>
          <population>Intention-to-treat</population>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="21.7"/>
                    <measurement group_id="O2" value="28.7" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Steroids</title>
          <description>Prednisone</description>
        </group>
        <group group_id="E2">
          <title>IT Steroids</title>
          <description>methylprednisolone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <description>Osteomyelitis of toe</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" events="186" subjects_affected="70" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" events="49" subjects_affected="35" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Eaer infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Tympnaic membrane perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="36" subjects_at_risk="125"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Appetite change</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="125"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Rauch</name_or_title>
      <organization>Massachusetts Eye and Ear Infirmary</organization>
      <phone>617-573-1166</phone>
      <email>steven_rauch@meei.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

